CY1120573T1 - Παραγωγα πυριδαζινης για χρηση στην προληψη ή θεραπεια αταξικης διαταραχης - Google Patents
Παραγωγα πυριδαζινης για χρηση στην προληψη ή θεραπεια αταξικης διαταραχηςInfo
- Publication number
- CY1120573T1 CY1120573T1 CY20181100843T CY181100843T CY1120573T1 CY 1120573 T1 CY1120573 T1 CY 1120573T1 CY 20181100843 T CY20181100843 T CY 20181100843T CY 181100843 T CY181100843 T CY 181100843T CY 1120573 T1 CY1120573 T1 CY 1120573T1
- Authority
- CY
- Cyprus
- Prior art keywords
- prevention
- pyridazine
- classical
- products
- disorder treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1403944.0A GB201403944D0 (en) | 2014-03-06 | 2014-03-06 | New use |
| PCT/GB2015/050654 WO2015132608A1 (en) | 2014-03-06 | 2015-03-06 | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1120573T1 true CY1120573T1 (el) | 2019-07-10 |
Family
ID=50554599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20181100843T CY1120573T1 (el) | 2014-03-06 | 2018-08-10 | Παραγωγα πυριδαζινης για χρηση στην προληψη ή θεραπεια αταξικης διαταραχης |
Country Status (32)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
| GB201222711D0 (en) | 2012-12-17 | 2013-01-30 | Takeda Pharmaceutical | Novel compounds |
| PE20211761A1 (es) | 2014-04-29 | 2021-09-07 | Fmc Corp | Herbicidas de piridazinona |
| TWI785022B (zh) | 2017-03-28 | 2022-12-01 | 美商富曼西公司 | 新穎噠嗪酮類除草劑 |
| BR112019028016B1 (pt) | 2017-06-30 | 2023-12-05 | Fmc Corporation | Composto, composições herbicidas, mistura herbicida e método para controlar o crescimento de vegetação indesejada |
| CN112569217B (zh) * | 2019-09-30 | 2022-04-22 | 厦门大学 | 戊酸衍生物在治疗遗传性小脑共济失调中的应用 |
| JP2021138648A (ja) | 2020-03-04 | 2021-09-16 | 武田薬品工業株式会社 | 経口固形製剤 |
| EP4301367A1 (en) | 2021-03-01 | 2024-01-10 | Takeda Pharmaceutical Company Limited | Use of luvadaxistat for the treatment of cognitive impairment |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1084704B1 (en) * | 1998-06-10 | 2006-03-29 | Meiji Seika Kaisha Ltd. | Remedies for spinocerebellar ataxia and compositions for treating spinocerebellar ataxia |
| AU2002339696A1 (en) * | 2001-12-03 | 2003-06-17 | Genset S.A. | Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors |
| JO3115B1 (ar) * | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
-
2014
- 2014-03-06 GB GBGB1403944.0A patent/GB201403944D0/en not_active Ceased
-
2015
- 2015-03-05 TW TW104106995A patent/TW201534591A/zh unknown
- 2015-03-06 MY MYPI2016703081A patent/MY202127A/en unknown
- 2015-03-06 JP JP2016555645A patent/JP6510549B2/ja not_active Expired - Fee Related
- 2015-03-06 GE GEAP201514284A patent/GEP20196984B/en unknown
- 2015-03-06 RS RS20180927A patent/RS57594B1/sr unknown
- 2015-03-06 WO PCT/GB2015/050654 patent/WO2015132608A1/en not_active Ceased
- 2015-03-06 SG SG11201607106YA patent/SG11201607106YA/en unknown
- 2015-03-06 KR KR1020167027639A patent/KR20160126081A/ko not_active Withdrawn
- 2015-03-06 MX MX2016010524A patent/MX2016010524A/es unknown
- 2015-03-06 EA EA201691566A patent/EA036438B1/ru unknown
- 2015-03-06 LT LTEP15709324.6T patent/LT3113778T/lt unknown
- 2015-03-06 PT PT157093246T patent/PT3113778T/pt unknown
- 2015-03-06 GE GEAP201914284A patent/GEAP201914284A/en unknown
- 2015-03-06 SI SI201530291T patent/SI3113778T1/en unknown
- 2015-03-06 PL PL15709324T patent/PL3113778T3/pl unknown
- 2015-03-06 DK DK15709324.6T patent/DK3113778T3/en active
- 2015-03-06 ES ES15709324.6T patent/ES2676905T3/es active Active
- 2015-03-06 CN CN201580012352.1A patent/CN106102743A/zh active Pending
- 2015-03-06 SM SM20180367T patent/SMT201800367T1/it unknown
- 2015-03-06 MA MA39315A patent/MA39315A1/fr unknown
- 2015-03-06 HR HRP20181082TT patent/HRP20181082T1/hr unknown
- 2015-03-06 CA CA2940342A patent/CA2940342A1/en not_active Abandoned
- 2015-03-06 US US15/123,796 patent/US20170014407A1/en not_active Abandoned
- 2015-03-06 EP EP15709324.6A patent/EP3113778B1/en active Active
- 2015-03-06 TR TR2018/09537T patent/TR201809537T4/tr unknown
- 2015-03-06 UA UAA201608758A patent/UA123352C2/uk unknown
- 2015-03-06 AU AU2015225954A patent/AU2015225954B2/en not_active Ceased
-
2016
- 2016-07-06 ZA ZA2016/04611A patent/ZA201604611B/en unknown
- 2016-08-23 IL IL247435A patent/IL247435A0/en active IP Right Grant
- 2016-08-25 CL CL2016002151A patent/CL2016002151A1/es unknown
- 2016-09-06 PH PH12016501751A patent/PH12016501751A1/en unknown
-
2018
- 2018-08-10 CY CY20181100843T patent/CY1120573T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1127661T1 (el) | Αρυλικες, ετεροαρυλικες και ετεροκυκλικες ενωσεις για τη θεραπευτικη αντιμετωπιση διαταραχων που διαμεσολαβουνται απο το συμπληρωμα | |
| CY1123592T1 (el) | Αναστολεας κινασης aurora a | |
| CY1122255T1 (el) | Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος | |
| ECSP17073743A (es) | Moduladores de k-ras | |
| MX394380B (es) | Compuestos dinucleótidos cíclicos para eltratamiento de cáncer | |
| CY1121534T1 (el) | Ενωσεις διυδροβενζοφουρανιου χρησιμες στην αγωγη του διαβητη και της παχυσαρκιας | |
| UY34750A (es) | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. | |
| CY1121554T1 (el) | Παραγωγο πυρανοχρωμενυλ-φαινολης, και φαρμακευτικη συνθεση για αγωγη μεταβολικου συνδρομου ή φλεγμονωδους παθησης | |
| CL2016003422A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| TR201813877T4 (tr) | Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler. | |
| MX2016012574A (es) | Compuestos heteroarilo sustituidos y metodos de uso. | |
| CL2016003423A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| EA201790627A1 (ru) | СТИМУЛЯТОРЫ рГЦ | |
| HRP20181490T1 (hr) | Spojevi 1, 3, 4-tiadiazola i njihova upotreba u liječenju raka | |
| MX2016009663A (es) | Derivados de icariina. | |
| EA201691412A1 (ru) | Гидроксиформамидные производные и их применение | |
| PH12016501751A1 (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder | |
| MX2016014859A (es) | Composiciones farmaceuticas que comprenden danirixina para tratar enfermedades infecciosas. | |
| CY1119532T1 (el) | (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
| JOP20190163B1 (ar) | منشط nrf2 | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы | |
| BR112017020374A2 (pt) | compostos bicíclicos fundidos para o tratamento de doença | |
| IL258610B (en) | Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use in the treatment of cancer |